The expression of Galectin-3 in breast cancer and its association with metastatic disease: a systematic review of the literature.
Breast cancer
Galectin-3
Metastasis
Metastatic disease
Recurrence
Journal
Molecular biology reports
ISSN: 1573-4978
Titre abrégé: Mol Biol Rep
Pays: Netherlands
ID NLM: 0403234
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
21
09
2020
accepted:
22
12
2020
pubmed:
6
1
2021
medline:
21
5
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
Breast cancer is the most common form of cancer and the second highest cause of cancer mortality in female patients. The significance of the expression of Galectin-3 has been correlated with various malignancy types and in data from several research papers, the expression of Galectin-3 has been associated with the progression and metastasis of breast cancer. In the present study, the authors' goal is to identify whether the expression of Galectin-3 in breast cancer can be associated with the presence and/or recurrence of a metastatic disease. Both Scopus and PubMed databases were utilized, by inputting the following combination of keywords: (((Breast) AND Metastasis)) AND ((Galectin 3) OR Galectin-3). The time of publication and text availability were not considered when searching the databases and all relevant articles in English were initially accepted. We included one case-control study, three retrospective case studies and one retrospective cohort study. In two of the included studies, the levels in concentration of Galectin-3 were not correlated with a significant difference in prognosis. In two studies, the lacking in expression of Galectin-3 was associated with a worse prognosis and in one of the studies selected, the elevated levels of Galectin-3 were correlated with recurrence of disease in triple negative breast cancer cases. For most of the studies selected for this review, the results were contradictory in regard to the role of Galectin-3 for prognosis and metastatic potential in female breast cancer patients. It is still unclear, whether Galectin-3 can be used as a prognostic marker for advanced breast cancer disease.
Identifiants
pubmed: 33398681
doi: 10.1007/s11033-020-06122-x
pii: 10.1007/s11033-020-06122-x
doi:
Substances chimiques
Blood Proteins
0
Galectins
0
LGALS3 protein, human
0
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
807-815Références
Liu FT, Rabinovich GA (2005) Galectins as modulators of tumour progression. Nat Rev Cancer 5(1):29–41
doi: 10.1038/nrc1527
Barondes SH, Castronovo V, Cooper DN, Cummings RD, Drickamer K, Feizi T et al (1994) Galectins: a family of animal beta-galactoside-binding lectins. Cell 76(4):597–598
doi: 10.1016/0092-8674(94)90498-7
Takenaka Y, Fukumori T, Raz A (2002) Galectin-3 and metastasis. Glycoconj J 19(7–9):543–549
doi: 10.1023/B:GLYC.0000014084.01324.15
Yang RY, Liu FT (2003) Galectins in cell growth and apoptosis. Cell Mol Life Sci 60(2):267–276
doi: 10.1007/s000180300022
Boutas I, Potiris A, Brenner W, Lebrecht A, Hasenburg A, Kalantaridou S et al (2019) The expression of galectin-3 in breast cancer and its association with chemoresistance: a systematic review of the literature. Arch Gynecol Obstet 300(5):1113–1120
doi: 10.1007/s00404-019-05292-9
Gillenwater A, Xu XC (1996) el-Naggar AK, Clayman GL, Lotan R. expression of galectins in head and neck squamous cell carcinoma. Head Neck 18(5):422–432
doi: 10.1002/(SICI)1097-0347(199609/10)18:5<422::AID-HED5>3.0.CO;2-7
Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, Yamaguchi S et al (2007) Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res 27(4B):2289–2296
pubmed: 17695516
Turkoz HK, Oksuz H, Yurdakul Z, Ozcan D (2008) Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. Endocr Pathol 19(2):92–96
doi: 10.1007/s12022-008-9033-3
Kim SJ, Shin JY, Cheong TC, Choi IJ, Lee YS, Park SH et al (2011) Galectin-3 germline variant at position 191 enhances nuclear accumulation and activation of beta-catenin in gastric cancer. Clin Exp Metastasis 28(8):743–750
doi: 10.1007/s10585-011-9406-8
Chen YR, Juan HF, Huang HC, Huang HH, Lee YJ, Liao MY et al (2006) Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 5(10):2727–2742
doi: 10.1021/pr060212g
Shekhar MP, Nangia-Makker P, Tait L, Miller F, Raz A (2004) Alterations in galectin-3 expression and distribution correlate with breast cancer progression: functional analysis of galectin-3 in breast epithelial-endothelial interactions. Am J Pathol 165(6):1931–1941
doi: 10.1016/S0002-9440(10)63245-2
Castronovo V, Van Den Brule FA, Jackers P, Clausse N, Liu FT, Gillet C et al (1996) Decreased expression of galectin-3 is associated with progression of human breast cancer. J Pathol 179(1):43–48
doi: 10.1002/(SICI)1096-9896(199605)179:1<43::AID-PATH541>3.0.CO;2-N
Idikio H (1998) Galectin-3 expression in human breast carcinoma: correlation with cancer histologic grade. Int J Oncol 12(6):1287–1290
pubmed: 9592187
Balan V, Wang Y, Nangia-Makker P, Kho D, Bajaj M, Smith D et al (2013) Galectin-3: a possible complementary marker to the PSA blood test. Oncotarget 4(4):542–549
doi: 10.18632/oncotarget.923
Eliaz I (2013) The role of Galectin-3 as a marker of Cancer and inflammation in a stage IV ovarian Cancer patient with underlying pro-inflammatory comorbidities. Case Rep Oncol 6(2):343–349
doi: 10.1159/000353574
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin
Honjo Y, Nangia-Makker P, Inohara H, Raz A (2001) Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. Clin Cancer Res 7(3):661–668
pubmed: 11297262
Song YK, Billiar TR, Lee YJ (2002) Role of galectin-3 in breast cancer metastasis: involvement of nitric oxide. Am J Pathol 160(3):1069–1075
doi: 10.1016/S0002-9440(10)64927-9
Topcu TO, Kavgaci H, Gunaldi M, Kocoglu H, Akyol M, Mentese A et al (2018) The clinical importance of serum galectin-3 levels in breast cancer patients with and without metastasis. J Cancer Res Ther 14(Supplement):S583–S5S6
pubmed: 30249872
Barrow H, Guo X, Wandall HH, Pedersen JW, Fu B, Zhao Q et al (2011) Serum galectin-2, −4, and −8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17(22):7035–7046
doi: 10.1158/1078-0432.CCR-11-1462
Yamaki S, Fujii T, Yajima R, Hirakata T, Yamaguchi S, Fujisawa T et al (2013) Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer. Surg Today 43(8):901–905
doi: 10.1007/s00595-012-0378-3
Fernandez-Aguilar S, Noel JC (2008) Expression of cathepsin D and galectin 3 in tubular carcinomas of the breast. APMIS 116(1):33–40
doi: 10.1111/j.1600-0463.2008.00753.x
Grosset AA, Labrie M, Vladoiu MC, Yousef EM, Gaboury L, St-Pierre Y (2016) Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget 7(14):18183–18203
doi: 10.18632/oncotarget.7784
Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7–30
doi: 10.3322/caac.21590
Fiorica JV (2016) Breast Cancer screening, mammography, and other modalities. Clin Obstet Gynecol 59(4):688–709
doi: 10.1097/GRF.0000000000000246
Mayoral MA, Mayoral C, Meneses A, Villalvazo L, Guzman A, Espinosa B et al (2008) Identification of galectin-3 and mucin-type O-glycans in breast cancer and its metastasis to brain. Cancer Investig 26(6):615–623
doi: 10.1080/07357900701837051
Moisa A, Fritz P, Eck A, Wehner HD, Murdter T, Simon W et al (2007) Growth/adhesion-regulatory tissue lectin galectin-3: stromal presence but not cytoplasmic/nuclear expression in tumor cells as a negative prognostic factor in breast cancer. Anticancer Res 27(4B):2131–2139
pubmed: 17695496
Tas F, Bilgin E, Tastekin D, Erturk K, Duranyildiz D (2016) Clinical significance of serum Galectin-3 levels in gastric Cancer patients. J Gastrointest Cancer 47(2):182–186
doi: 10.1007/s12029-016-9817-5
Kataoka Y, Igarashi T, Ohshio Y, Fujita T, Hanaoka J (2019) Predictive importance of galectin-3 for recurrence of non-small cell lung cancer. Gen Thorac Cardiovasc Surg 67(8):704–711
doi: 10.1007/s11748-019-01074-x
Ulu M, Alacacioglu A, Yuksel E, Pamukk BO, Bozkaya G, Ari A et al (2015) Prognostic significance of serum galectin-3 levels in patients with hepatocellular cancer and chronic viral hepatitis. Saudi J Gastroenterol 21(1):47–50
doi: 10.4103/1319-3767.151228
Funasaka T, Raz A, Nangia-Makker P (2014) Galectin-3 in angiogenesis and metastasis. Glycobiology 24(10):886–891
doi: 10.1093/glycob/cwu086
Ilmer M, Mazurek N, Gilcrease MZ, Byrd JC, Woodward WA, Buchholz TA et al (2016) Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells. Breast Cancer Res 18(1):97
doi: 10.1186/s13058-016-0757-6
Romero A, Gabius HJ (2019) Galectin-3: is this member of a large family of multifunctional lectins (already) a therapeutic target? Expert Opin Ther Targets 23(10):819–828
doi: 10.1080/14728222.2019.1675638
John CM, Leffler H, Kahl-Knutsson B, Svensson I, Jarvis GA (2003) Truncated galectin-3 inhibits tumor growth and metastasis in orthotopic nude mouse model of human breast cancer. Clin Cancer Res 9(6):2374–2383
pubmed: 12796408
Liu XH, Deng CX, Hu PC, Wang Y, Dong YH (2017) Functional impact of Galectin-3 and TRAIL expression in breast cancer cells. Eur Rev Med Pharmacol Sci 21(16):3626–3633
pubmed: 28925481